In that study, mutant KRAS knockdown inactivated the MEK-ERK pathway in a common manner, but resulted in variable changes in RAS-related signaling (e.g., changes in phospho-EGFR levels and phospho-Akt levels), and sensitized KRAS-mutated NSCLC cells to p38 and EGFR inhibitors to varying degrees. Here, KRAS is linked to non-small cell lung carcinoma.